Literature DB >> 14665873

Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.

Carsten Stephan1, George M Yousef, Andreas Scorilas, Klaus Jung, Monika Jung, Glen Kristiansen, Steffen Hauptmann, Tadaaki Kishi, Terukazu Nakamura, Stefan A Loening, Eleftherios P Diamandis.   

Abstract

PURPOSE: Other cDNA microarray studies have shown that hepsin is one of the highly over expressed genes in prostate cancer tissue compared with nonmalignant and benign prostatic hyperplasia tissue. We quantitatively analyzed hepsin gene expression with real-time polymerase chain reaction and calculated its relationships with clinicopathological parameters in a large cohort of samples.
MATERIALS AND METHODS: Matched prostate tissue samples from the cancerous and noncancerous parts of the same prostates were obtained from 90 patients with prostate cancer who underwent radical prostatectomy. Quantitative reverse transcriptase-polymerase chain reaction was performed using LightCycler Fast Start DNA Master SYBR Green I on a LightCycler (Roche Diagnostics GmbH, Mannheim, Germany) system. The ratio of hepsin-to-beta-actin (a housekeeping gene) was used to normalize data.
RESULTS: Hepsin over expression in cancerous compared with noncancerous tissue was found in 81 of the 90 patient samples (90%, p <0.001). In 48 patients (53%) hepsin over expression was more than 10-fold in cancerous tissue. The ratio of cancerous-to-noncancerous hepsin expression was significantly higher in the 39 patients with grade 3 tumors compared with the 51 with grade 2 tumors (median 15.5 vs 9.6, p = 0.031). For the prognosis a cutoff at the 75th percentile provided a significant difference between patients at lower risk (pT2, G2 and Gleason score less than 7) and higher risk (pT3/4, G3 and Gleason score 7 or greater) for relapse.
CONCLUSIONS: This report of the quantitative analysis of hepsin expression, which is the first to our knowledge, shows strong and significant over expression in prostate cancer tissue. Hepsin expression may be a new prognostic marker that could be used for assessing prostate cancer aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14665873     DOI: 10.1097/01.ju.0000101622.74236.94

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Rapid and sensitive detection of single cryptosporidium oocysts from archived glass slides.

Authors:  O Sunnotel; W J Snelling; L Xiao; K Moule; J E Moore; B Cherie Millar; J S G Dooley; C J Lowery
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

2.  Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Authors:  Stephanie M Wittig-Blaich; Lukasz A Kacprzyk; Thorsten Eismann; Melanie Bewerunge-Hudler; Petra Kruse; Eva Winkler; Wolfgang S L Strauss; Raimund Hibst; Rudolf Steiner; Mark Schrader; Daniel Mertens; Holger Sültmann; Rainer Wittig
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

3.  Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Authors:  Prodipto Pal; Huifeng Xi; Saurav Guha; Guangyun Sun; Brian T Helfand; Joshua J Meeks; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

4.  Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Authors:  Sylvia Herter; Derek E Piper; Wade Aaron; Timothy Gabriele; Gene Cutler; Ping Cao; Ami S Bhatt; Youngchool Choe; Charles S Craik; Nigel Walker; David Meininger; Timothy Hoey; Richard J Austin
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

5.  Variants in the HEPSIN gene are associated with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Ritesh Kaushal; Guangyun Sun; Carol H Jin; Li Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2006-06-17       Impact factor: 4.132

Review 6.  Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

Authors:  Srinivas Nandana; Leland Wk Chung
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

7.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

8.  Accurate molecular classification of cancer using simple rules.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  BMC Med Genomics       Date:  2009-10-30       Impact factor: 3.063

9.  Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Authors:  Srinivas Nandana; Katharine Ellwood-Yen; Charles Sawyers; Marcia Wills; Brandy Weidow; Thomas Case; Valeri Vasioukhin; Robert Matusik
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

10.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.